2,4-Diamino-6-hexahydroazepinyl-s-triazin | 13348-85-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,4-Diamino-6-hexahydroazepinyl-s-triazin
• 英文别名: 6-azepan-1-yl-[1,3,5]triazine-2,4-diamine；6-(Azepan-1-yl)-1,3,5-triazine-2,4-diamine
• CAS: 13348-85-1
• 化学式: C₉H₁₆N₆
• 分子量: 208.266
• InChiKey: AKWLFMXGNQEZTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  94
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Medical devices employing triazine compounds and compositions thereof
  申请人：Timmer T. Richard

  公开号：US20050113341A1

  公开（公告）日：2005-05-26

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及使用化合物治疗由炎症反应引起的病理生理状态的方法和组合物。具体而言，本发明涉及抑制或阻断糖基化蛋白质诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。具体而言，本发明涉及通过调节HSPGs，如Perlecan，抑制平滑肌细胞增殖的化合物。本发明还涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化。
• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20060258641A1

  公开（公告）日：2006-11-16

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状态的化合物的方法和组合物。特别地，本发明涉及抑制或阻断糖基化蛋白质诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别地，本发明涉及通过调节HSPG（如Perlecan）抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉硬化。
• Improvements in or relating to textile printing and dyeing
  申请人：BASF AUSTRALIA LTD

  公开号：EP0264308A2

  公开（公告）日：1988-04-20

  A process is provided for direct colouring of textile fibres comprising appropriately pre-treating said fibres, preparing a solution of a cross-linking agent being a solution of a water insoluble technical hexamethoxymethyl melamine in a C4-8 glycol, adding said solution of the cross-linking agent to a dye liquor or printing paste containing a colourant (excluding cationic dyestuffs) in the presence of an acid donor, applying the resultant mixture to said fibres and drying and curing said fibres. Also provided is a dye liquor or print paste comprising a colourant (excluding cationic dyestuffs), an acid donor and a cross-linking agent being a solution of a water insoluble technical hexamethoxymethyl melamine in a C4-8 glycol.

  提供了一种用于纺织纤维直接着色的工艺，包括适当预处理所述纤维，制备一种交联剂溶液（一种不溶于水的工业级六甲氧基甲基三聚氰胺在 C4-8 乙二醇中的溶液），将所述交联剂溶液添加到含有着色剂（不包括阳离子染料）的染料液或印花浆中，同时存在一种酸供体，将所得混合物涂抹到所述纤维上，并干燥和固化所述纤维。 此外，还提供了一种染色液或印花浆，其中包含着色剂（不包括阳离子染料）、酸供体和交联剂，交联剂是不溶于水的工业级六甲氧基甲基三聚氰胺在 C4-8 二醇中的溶液。
• [EN] METHOD FOR ENCAPSULATING DRUG WITHIN FERRITIN, AND PRODUCT THEREOF<br/>[FR] PROCÉDÉ D'ENROBAGE D'UN MÉDICAMENT DANS UNE FERRITINE ET PRODUIT ASSOCIÉ<br/>[ZH] 铁蛋白包载药物的方法及其产物
  申请人：KUNSHAN XINYUNDA BIOTECH CO LTD

  公开号：WO2019170059A1

  公开（公告）日：2019-09-12

  本发明涉及铁蛋白包载药物的方法及其产物。具体而言，本发明通过具体探索不同浓度的SDS或盐酸胍或脲、不同的处理温度和/或不同的处理时间对铁蛋白如全人铁蛋白解聚和复聚的影响，研究了利用铁蛋白包载药物如阿霉素的最佳条件。利用本发明所获得的包载条件，可以方便、快捷、高效、足量地利用铁蛋白包载药物。
• [EN] CRYSTAL FORM OF MONOMETHANESULFONATE OF DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL COMPOUND, AND PREPARATION METHOD THEREFOR<br/>[FR] FORME CRISTALLINE DE MONOMÉTHANESULFONATE D'UN COMPOSÉ DEUTÉRÉ DE 3-(AMINOPYRIMIDINE 4,5-SUBSTITUÉ)PHÉNYLE, ET PROCÉDÉ DE PRÉPARATION ASSOCIÉ<br/>[ZH] 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法
  申请人：NANJING CHUANGTE PHARMACEUTICAL TECH CO LTD

  公开号：WO2019174623A1

  公开（公告）日：2019-09-19

  本发明公开了一种结构如式I氘代3-(4,5-取代氨基嘧啶)苯基化合物的单甲磺酸盐晶型及其制备方法，所述晶型稳定性高，可通过某些突变形式的表皮生长因子受体而用于疾病或病况的治疗或预防，可以有效抑制多种肿瘤细胞的生长，并对EGFR、Her家族其他蛋白酶产生抑制作用，可用于制备抗肿瘤药物。